A 2026 partnering scan of AbClon, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.

A 2026 partnering scan of ABION, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.

A 2026 partnering scan of A&G Pharmaceutical, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.

A 2026 partnering scan of 4SC AG, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bexmarilimab, an antibody targeting STAB1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Giloralimab, an antibody targeting TNFRSF5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zeluvalimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Avizakimab, an antibody targeting IL21.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Benufutamab, an antibody targeting TNFRSF10B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lonigutamab, an antibody targeting IGF1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nivatrotamab, an antibody targeting GD2 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Omodenbamab, an antibody targeting Staphylococcus aureus Protein A.